40,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

The majority of breast cancers are sporadic while 5-10% are due to an inherited predisposition. The identification of the BRCA1 and BRCA2 genes, which confer a high risk of developing breast and/or ovarian cancer, has led to a better understanding of familial forms of breast cancer. Estimates of the prevalence and penetrance of BRCA1 and BRCA2 mutations vary greatly depending on the populations studied, the study strategies, and the sensitivity of the mutation detection methods.Our work consisted of a retrospective study of 40 cases through oncogenetic consultation and molecular explorations…mehr

Produktbeschreibung
The majority of breast cancers are sporadic while 5-10% are due to an inherited predisposition. The identification of the BRCA1 and BRCA2 genes, which confer a high risk of developing breast and/or ovarian cancer, has led to a better understanding of familial forms of breast cancer. Estimates of the prevalence and penetrance of BRCA1 and BRCA2 mutations vary greatly depending on the populations studied, the study strategies, and the sensitivity of the mutation detection methods.Our work consisted of a retrospective study of 40 cases through oncogenetic consultation and molecular explorations of BRCA1 and BRCA2 genes at the medical genetic laboratory of the Hassan II University Hospital in Fez, during a period of 5 years; between January 2010 and December 2015. The aim of this study is to highlight the place of the clinical and molecular oncogenetic approach in the management of patients and families with hereditary predisposition to breast and/or ovarian cancer.
Autorenporträt
Narjisse El Rhouizi nació el 19 de noviembre de 1990. Estudió medicina en la Universidad Sidi Mohammed Ben Abdellah de Fez (Marruecos) y se licenció (doctora) en 2016. A continuación, comenzó sus estudios de especialización en Alemania.